Prevalence and determinants of adherence to statin therapy: a systematic review and meta-analysis - Takeaways - MDSpire

Prevalence and determinants of adherence to statin therapy: a systematic review and meta-analysis

  • By

  • Athanasios Basios

  • Georgios Markozannes

  • Evangelia E Ntzani

  • Konstantinos Christopoulos

  • Christina A Chatzi

  • Evangelos Liberopoulos

  • Konstantinos K Tsilidis

  • Maria Pappa

  • Evangelos C Rizos

  • December 16, 2025

  • 0 min

Share

  • 1

    The pooled prevalence of good adherence to statin therapy was 62.4%, with lower rates in primary prevention compared to secondary prevention.

  • 2

    Demographic factors such as female sex, Black race, smoking, and depression were associated with lower adherence to statin therapy.

  • 3

    Higher adherence was observed among older adults and those with a history of myocardial infarction, hypertension, or multiple comorbidities.

  • 4

    Polypharmacy was linked to greater adherence, possibly due to increased medical supervision or perceived cardiovascular risk.

  • 5

    Targeted interventions are necessary to improve statin adherence, especially among high-risk groups to reduce cardiovascular morbidity and mortality.

Original Source(s)

Prevalence and determinants of adherence to statin therapy: a systematic review and meta-analysis

  • by Athanasios Basios, Georgios Markozannes, Evangelia E Ntzani, Konstantinos Christopoulos, Christina A Chatzi, Evangelos Liberopoulos, Konstantinos K Tsilidis, Maria Pappa, Evangelos C Rizos

  • December 16, 2025

Related Content

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

The insulin resistance-systemic vascular resistance-isolated diastolic hypertension axis: a metabolic framework for an overlooked hypertension phenotype

Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins